NUVL
Nuvalent, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -11.1% ·
aandelenstroom +2.8% ·
netto nieuwe posities -18.8%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +1 | 28.33M | $3.50B | +17 | −15 |
| Q1 2026 | 98 | +7 | 37.97M | $3.87B | +12 | −6 |
| Q4 2025 | 90 | +2 | 41.80M | $4.20B | +4 | −1 |
| Q3 2025 | 16 | -2 | 30.34M | $2.62B | +1 | −4 |
| Q2 2025 | 16 | -1 | 25.82M | $1.97B | n/a | −1 |
| Q1 2025 | 14 | +1 | 6.74M | $477.77M | +1 | n/a |
| Q4 2024 | 13 | +1 | 7.00M | $548.03M | +1 | n/a |
| Q3 2024 | 11 | +1 | 4.59M | $469.19M | +1 | n/a |
| Q2 2024 | 10 | n/a | 3.29M | $249.85M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 10.01M | +0.5% | $865.94M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | The Vanguard Group ✦ (passief) | 4.61M | +1.8% | $398.24M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (passief) | 4.09M | +1.0% | $353.34M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 4 | JPMorgan Chase ✦ | 3.35M | n/a | $289.54M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 5 | Wellington Management ✦ | 2.30M | +46.0% | $198.98M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 6 | T. Rowe Price ✦ | 1.81M | +0.8% | $156.57M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passief) | 1.57M | +5.7% | $136.18M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passief) | 1.09M | +9.8% | $94.62M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Adage Capital Partners ✦ | 574.50K | -0.5% | $49.68M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 444.44K | n/a | $38.43M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 275.11K | n/a | $23.79M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 12 | Fisher Asset Management ✦ | 106.42K | -7.3% | $9.20M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 30.23K | -52.6% | $2.61M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 27.66K | -17.9% | $2.39M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 27.31K | -82.6% | $2.36M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 22.06K | Nieuw | $1.91M | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $1.91M | 0.0% |
Verlaten
| Norges Bank | $28.58M | was 0.0% |
| Marshall Wace | $4.69M | was 0.0% |
| Renaissance Technologies | $2.23M | was 0.0% |
| Two Sigma Investments | $683,572 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 262 houders, 78.13M aandelen, $7.62B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.